Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Cardiol Therapeutics

Tracked across 2 events · 12 articles · First seen Aug 05, 2026 · Last active Sep 23, 2026

Sentiment
12
Attention
2
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
0 10
Business
Impact: Cardiol Therapeutics is the subject of the announcement, participating in the conference to present its clinical programs. This is a routine investor relations activity with no expected material impact on its stock.
Aug 05, 2026 · 6 articles
2 15
Tech
Cardiol Therapeutics Inc. announced on September 23, 2026 that its pivotal Phase III MAVERIC trial of CardiolRx for recurrent pericarditis reached its original 110-patient enrollment target ahead of end-of-September guidance. Following a blinded review showing…
Impact: The company is the central actor, achieving its Phase III enrollment target early and expanding the MAVERIC trial to up to 150 patients. The delayed topline timeline to mid-2027 and extended cash runway into Q1 2028 shape its near-term valuation.
Sep 23, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Cardiol Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.